Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 6101-6110 Newer>

Registered Rep. March 1, 2005 Will Leitch	A Sporting Chance Morgan's shareholders are testy now, and they are looking for someone to blame for the company's ills. Having taken a 46% raise in a year in which his company's stock dropped 8.2 percent, chairman and CEO Philip Purcell makes an easy target.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
InternetNews March 2, 2005 Colin C. Haley	Verizon Gives MCI 2 Weeks For Qwest Talks Verizon is confident MCI will conclude that a Verizon-MCI deal is more compelling than a Qwest-MCI combination in terms of long term prospects - despite a lower price tag.
The Motley Fool March 2, 2005 Bill Mann	Less Margin for Error at Costco Almost everything looks good for Costco. So, what was the problem with the retailer's second-quarter earnings report? Investors, take note.
The Motley Fool March 2, 2005 Nathan Slaughter	Papa John's Outlook Rising Pizza chain reports flat 2004 revenues, but year ahead holds promise. Earnings per share jumped to $0.73, topping estimates by a nickel.
The Motley Fool March 2, 2005 Tom Taulli	Interchange's Keyword: "Sell" Search is still growing fast. But competition is making it tough for the small players. Interchange's stock plunged 34.53% to $13.53. Keep in mind that late last year, it hit a high of $31.77.
The Motley Fool March 2, 2005 W.D. Crotty	Overpriced Natural Foods United Natural Foods is growing rapidly, but its stock is priced at a premium.
The Motley Fool March 2, 2005 Brant David McLaughlin	Merck's Road to Recovery Merck didn't get to where it is by being shortsighted, and management has no plans to start now. Investors would be wise not to take on an excessively negative attitude toward the company in the wake of some dark news.
The Motley Fool March 2, 2005 Bill Mann	How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns.
The Motley Fool March 2, 2005 Bill Mann	First, Shoot All the Chartists Citigroup fired their technical analysts not because of their work product, but because of a lack of revenues derived from their output. That, not any underperformance issues, is the unforgivable sin.
<Older 6101-6110 Newer> Return to current articles.